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Sneddon’s syndrome (SS) is a rare non-inflammatory thrombotic vasculopathy characterized by the combination of
cerebrovascular disease with livedo racemosa(LR). The Orpha number for SS is ORPHA820. It has been estimated that
the incidence of SS is 4 per 1 million per annum in general population and generally occurs in women between the
ages of 20 and 42 years. LR may precede the onset of stroke by years and the trunk and/or buttocks are involved in
nearly all patients. The cerebrovascular manifestations are mostly secondary to ischemia (transient ischemic attacks and
cerebral infarct). Other neurological symptoms range from headache, cerebral hemorrhage, seizures, cognitive and
psychiatric disturbances. The involved internal organs include heart, kidney, and eyes. Histological findings of skin are
characteristic and the involved vessels are small to medium-sized arteries at the border of dermis to subcutis with a
distinct histopathological time course. The main diagnostic criteria are general LR with typical histopathological findings
on skin biopsy and focal neurological deficits. The pathogenesis is related to hypercoagulable state and intrinsic
small-vessel vasculopathy. The optimal management remains an unsolved problem and long-term anticoagulation
have been recommended for cerebral ischemic events based on the presumed pathogenesis. There are controversial
results in treatment of SS with immunomodulatory agents. The aim of this review is to comprehensively discuss
this disease.
Keywords: Sneddon’s syndrome, Skin disease, Stroke, Systematic reviewIntroduction
Definition
Sneddon’s syndrome (SS) is a rare non-inflammatory
thrombotic vasculopathy characterized by the combin-
ation of cerebrovascular disease with livedo racemosa
(LR).History
The association between LR and cerebrovascular mani-
festation was first described by Kimming in 1959 [1]. In
1960, Champion and Rook described a case of cutaneous
condition, diffuse arterial occlusive disease and cerebral
ischemia [2]. 5 years later, Sneddon reported six patients
with severe and generalized bluish discoloration of the
skin (also termed as livedo reticularis), “multiple cerebro-
vascular incidents of limited and benign nature” and no
autopsy reported [3]. Since then the term SS has been* Correspondence: wen1937@sohu.com
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bral infarcts.Classification
SS, which originally was a clinical diagnosis, is now
regarded as a common clinical manifestation of different
disease entities. Three forms of the syndrome were
described by Schellong et al.: primary, where no causative
factor could be identified, autoimmune with antiphospholi-
pid antibodies (aPL) or coexisting systemic lupus erythe-
matosus (SLE) or lupus-like disease and a thrombophilic
form [4]. Francès et al. proposed that SS should be classi-
fied as idiopathic SS with neither aPL nor SLE, primary
antiphospholipid syndrome (APS)-related SS, and SLE
related SS with or without aPL [5]. Cases without any other
pathological signs except LR should be historically labeled
“idiopathic generalized LR” which may not exist as a separ-
ate entity but may represent a very early stage of SS.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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While a number of SS cases have been reported since
1965, there is no definite evidence of ethnic differences in
incidence. It has been estimated that the incidence of SS is
4 per 1 million per annum in general population [6]. In
hospital-based series of stroke patients, the frequency of SS
is between 0.25% and 0.50% [7,8]. A mortality rate of 9.5%
is reported in a mean observation period of 6.2 years [6].
SS generally occurs in women between the ages of 20
and 42 years. For example, in the serial studies reported
by Sneddon [3], 5 of 6 patients were women. Similarly, 34
of 46 patients were women reported by Francès and all
cases were women in the report by Bolayir [5,9]. However,
SS does occur occasionally in girls as young as 10 years
old and in women as advanced as 64 years old [10].
Genetic characteristics
The disorder mainly occurs sporadically, although a few
familial cases have been reported [11]. Hademonos et al.
[12] described in a review of the genetics of cerebrovascu-
lar disease and stroke that SS was inherited in an auto-
somal dominant pattern with unknown type of the gene
and gene chromosome localization. In familial cases de-
scribed by Rebollo et al. [13], either LR or full clinical SS
was apparently transmitted in autosomal dominant pat-
tern with complete or incomplete penetrance. The studies
by Zhou et al. and Navon Elkan et al. have identified novel
mutations in CECR1(cat eye syndrome chromosome
region, candidate 1), encoding ADA2, as the cause of a
syndrome including systemic vasculopathy and inflamma-
tion. Bras etal. extend the phenotypic spectrum of ADA2
deficiency to include a familial form of SS [14,15].
Clinical description
Dermatologic manifestations
One of the diagnostic hallmarks of SS is LR (Figure 1a).
LR is defined as a dusky erythematousto-violaceous,
irregular, net-like pattern in the skin. LR may precede the
onset of stroke by years and is located on limbs (100%
each), trunk (84–89%), buttocks (68–74%), face (15–16%),
or the hands or feet (53–59%) [5]. The trunk and/or
buttocks are involved in nearly all patients. LR is noticed
before cerebrovascular events in more than a half of
patients. In some patients, the livedo is first detected at
the time of stroke occurrence [16,17]. In rare cases, LR
appears after neurological symptoms [18]. In addition to
LR, some patients have signs of Raynaud’s phenomenon
involving hands and feet and some have widespread cuta-
neous, mottled-purple discoloration on the body which
had been diagnosed as systemic angiomatosis [19,20].
LR is similar to the familiar sign of livedo reticularis from
which it differs by its shape (irregular, broken circular
segments, resulting in a seemingly larger pattern), and per-
sistence on warming [21,22]. In the American literature,livedo reticularis is used interchangeably with LR despite
their different pathophysiological basis. Livedo reticularis is
caused by temporary vasoconstriction, whereas livedo race-
mosa results from persistent impairment of peripheral
blood flow caused by occlusion of small or medium-sized
arteries [23,24].
Neurological manifestations
Stroke is another diagnostic hallmark of SS. This cerebro-
vascular disease mostly occurs due to ischemia (transient
ischemic attacks and cerebral infarct) in the perfusion
zones of middle cerebral artery or posterior cerebral artery
[25,26]. Hemiparesis, sensory disturbances, aphasia and
visual field defects are the most common clinical signs.
However, most patients are minor stroke. Headache repre-
sents the most frequent unspecific symptom [27,28]. The
50% of these patients have migrainous headache [29]. The
frequency of headache is not significantly higher in per-
sons with positive aPL when compared to an aPL-negative
cohort [29].
Cognitive impairment and psychiatric disturbances can
occur in approximately 77% of SS patients and SS can also
be a cause of dementia in the young [25,30]. These
patients develop cognitive dysfunction over years and then
dementia due to the cumulative effects of multiple cere-
bral infarcts. Because of these features, SS may lead to
psychiatric disturbances, including depression. Concentra-
tion, attention, memory, visual perception and visuospatial
construction are the most commonly described cognitive
dysfunctions [31]. However, patients with SS can develop
topographic disorientation or dementia without ante-
cedent clinical stroke [18]. Focal or secondary generalized
seizures are commonly seen in SS, especially in patients
with positive aPL [5,32].
Intracerebral (ICH), subarachnoid or intraventricular
hemorrhage are unusual in SS. Movement disorders
including chorea and tremor were occasionally been
described [33,34].
Other manifestations
Hypertension occurs in a significant proportion (15%–65%)
of SS patients [25,26]. Heart valvulopathy was found in 41%
of SS patients in one study and 61% in another study
[35,26]. Mitral valve thickening has been revealed more
frequently in patients with aPL than in those without. Cases
of SS with ischemic heart disease are described including
patient associated with successful percutaneous coronary
intervention [36]. The renal function is slowly deteriorated
in SS. Zelger et al. reported a long-term follow-up of 21 pa-
tients and observed that 65% of patients showed decreased
levels of creatinine clearance [6].
Ophthalmologic complications include central retinal
artery occlusion, central retinal vein occlusion, retinal
neovascularization, homonymous visual field defects, and
Figure 1 (two cases of SS ) a, diffused livedo racemosa (asterisks); b, FLAIR/T2 MRI brain scan showing multiple ischemic lesions (white
arrows) and cortical atrophy (red arrows); c, skin biopsy showed intra-capillary (thin arrow) and parietal (thick arrow) widespread
thrombosis; scale bar 100μm (Case1) and 50 μm (Case2). (courtesy of Dr. Alessandro Tessitore).
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reported a young SS patient with internuclear ophtalmo-
plegia followed by ophthalmic artery occlusion [41]. Uni-
lateral third cranial nerve palsy has been seen in a patient
with SS and this is likely associated with microvascular
complication [43].
Etiology
The precise etiology is unknown and around 50% of
cases are idiopathic. Female reproductive hormones, oral
contraceptives and hypertension are correlated with dis-
ease progression. The frequent presence of aPL suggest
that SS is part of the clinical spectrum of the primary
aPL syndrome. The proportion of aPL antibodies is
widely different in various cohorts of SS [6,35,44]. The
majority authors suggest that 40–50% of SS patients areaPL positive [5,45]. However, some patients are aPL-
negative which indicate that this syndrome may be a
distinct entity or perhaps a group of different disorders.
Pathology
Dermatopathology
Skin biopsy is critically important for the early diagnosis
of SS. Skin biopsy may reveal thrombosis of subcutaneous
arterioles and compensatory capillary dilation with blood
stagnation causing LR (Figure 1c). Several lines of evi-
dence showed endarteritis obliterans from intimal endo-
thelial proliferation and proliferation of medial smooth
muscle cells [24,46,47], although skin biopsies were nega-
tive or non-specific in some cases [1,48]. Pathogenesis of
SS has been proposed a stepwise pattern of disease pro-
gression by Sepp et al. and Zelger et al. [49,50], beginning
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sizes of arteries. After the initial phase (stage I) of
endotheliitis, characterised by a plug, the formation of the
plug of lymphohistiocytic cells and fibrin would occur in
the early phase (II stage), followed by the intermediate
phase (stage III) of subendothelial migration of smooth
muscle cells, and completed by the late phase (stage IV) of
vessel shrinkage and fibrosis. Skin biopsy may reveal
different pathological phases in one patient. However, the
severity of the clinical findings is not normally correlated
with the histological findings. Deep skin biopsies increase
sensitivity from 27% with one biopsy, to 53% with two
biopsies, and to 80% with three biopsies taken from white
areas in the most of cases [51].
Brain pathology
Brain biopsy is rarely done in SS. The pathologic findings
showed multiple vascular thrombosis without vasculitis in
the first brain biopsy case [52]. There were cortical
infarcts and leukoencephalopathy associated with intimal
fibrosis of the basal vessels in a biopsy report [53]. The
other autopsy report described a diffuse vasculopathy
affecting small to medium sized arteries (including cere-
bral vessels) characterized by proliferation of the intima
and media, with some vessels showing fibrotic occlusion
and recanalization. Inflammation did not affect blood
vessels [54]. The principal pathologic findings in the case
reported by Hilton DA et al. were multiple small cortical
infarcts associated with occlusion of medium sized arteries
and prominent focal smooth muscle hyperplasia of smaller
arterial vessels [55]. Although a granulomatous reaction in
the leptomeninges has been reported [56], this reaction is
not observed by others [54], suggesting that this abnor-
mality does not always occur in SS.
Pathophysiology
Pathophysiology of SS remains incompletely understood
to date. The existence of aPL antibodies suggests that
symptoms are secondary to thrombotic process [57].
Vascular thrombosis and recanalization within skin and
brain tissue support the pathophysiology of coagulopathy.
Although a basic thrombotic process may appear in SS,
it is still not clear how it occurs in aPL-negative cases.
Various abnormalities have been reported in isolated
cases: activated protein C resistance [58], platelet aggre-
gability [49], increased thromboglobulin levels [59],
modifications of the ratio tissue plasminogen activator/in-
hibitor [60], familial deficiency in antithrombin III [46],
and protein S deficiency [61]. None of these abnormalities
have been confirmed in large series of studies. Protein Z, a
downregulator of coagulation and linked to an in-
creased risk of arterial thrombosis, is significantly low-
ered in patients with aPL-negative SS [62]. Heart valve
abnormalities, either clinically audible or detected onechocardiogram, are frequently observed, and their
total prevalence is similar in both groups. This raises
the possibility that the embolic mechanism plays an
important role in the occurrence of some neurologic
and even skin manifestations of SS [63].
In some patients, no aPL or primary coagulation deficits
are detected. Thus, the primary vasculopathy is considered
as the pathophysiological change in SS. It is speculated
that a nonvasculitic small and medium sized vessel arter-
iopathy causes both skin symptoms and cerebrovascular
events [48]. However, the type and origin of the arteriopa-
thy is largely unknown [64]. In some cases, the gene
responsible for the arteriopathy may play a role [41,65].
Besides, endothelial dysfunction may be secondary to
acquired autoimmune or mediated by some unknown
factors [66,67].
Diagnosis
Any patient suspected of SS should undergo blood tests,
thorough cardiovascular evaluation, cerebral MRI, cerebral
angiography, and skin biopsy. Blood tests should screen for
lupus anticoagulant, immunoglobulin IgG and possibly IgM
anti-cardiolipinantibodies, anti-nuclear and anti-double-stran
ded DNA autoantibodies, thrombocytopenia, leukopenia,
VDRL, cryoglobulins, circulating immune complexes, anti-
thrombin-III, protein C, or protein S [3,13,68,46]. The cere-
brospinal fluid (CSF) is usually normal.
Lesions can be more clearly detected by MRI than by
CT scan. These lesions are often small and multifocal,
located predominantly in the periventricular deep white
matter or pons (Figure 1b). Cerebral hemorrhages are
rarely found in SS. Prominent microbleeds are found in
familial SS, which might be a marker of impending haem-
orrhagic stroke [65,69]. Cerebral angiography is abnormal
up to 75% of patients with SS. The most common abnor-
mality is an obliterating noninflammatory arteriopathy
with stenosis and/or occlusion of intracranial vessels
[70-73]. Other reported findings include: arteriovenous
malformations involving meningeal branches, transdural
anastomoses, granulomatous leptomeningeal infiltration,
and a large network of fine collateral vessels [70-76].
Occurrence of an aneurysmatic dilatation of the ascending
aorta is rare in SS [77].
The main criteria are general LR with typical histo-
pathological findings on skin biopsy and focal neurological
deficits. Supportive criteria are a history of transient ische-
mic attacks or stroke and evidence of small bright foci on
T2-weighted MRI [68].
Differential diagnosis
Some diseases that can occur with generalized LR (such as
SLE, polyarteritis nodosa, cryoglobulinemia, livedoid vas-
culitis, cold agglutinin disease, arteriosclerosis, cholesterin
embolization and others [6,22,59]), must be excluded by
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diagnosis of neurological symptoms include multiple
sclerosis, multiple embolization from cardiac source,
infectious conditions (such as syphilis and lyme disease),
and others [6,43]. Central nervous system (CNS) vasculitis
refers to a broad array of diseases that result in inflamma-
tion and destruction of the blood vessels of brain, spinal
cord and the meninges. CNS vasculitis is classified into
systemic vasculitis and isolated CNS angiitis. CNS vascu-
litis may present symptoms such as headache and stroke
which mimic SS patients. However, in systemic vasculitis,
CNS involvement always coexists with other clearly appar-
ent systemic manifestations. Isolated CNS angiitis is twice
as frequent in males as in females and onset most often
occurs after 40 years of age. The sedimentation rate is
moderately increased in about 30% patients and CSF
inflammation is observed in about 90% of patients. Histo-
logical findings are characterized by infiltrations of the
vascular walls with mononuclear cells including lympho-
cytes, macrophages, and histiocytes [78].
Treatment
The optimal management of patients with SS remains
an unsolved issue and controlled trials have not yet been
performed. Although nifedipine may reduce skin symp-
toms, it does not prevent cerebrovascular complications
[6]. Based on the presumed pathogenesis of SS, some re-
searchers have recommended long-term anticoagulation
for cerebral ischemic events [79,80]. Khamashta et al. re-
ported in a retrospective study of 183 patients with APS
syndrome that the number of events per year of follow
up was 0.18 with aspirin, 0.23 with low dose warfarin
(INR < 3), and 0.015 with high-dose warfarin (INR ≥ 3).
In a retrospective study, Francès et al. found that anti-
platelet therapy was less effective in aPL-positive than in
aPL-negative patients. Among the former, the number of
recurrent cerebral events per year of follow-up was 0.5
with antiplatelet therapy and 0.06 with anticoagulation.
The three aPL-positive patients who experienced a new
cerebral ischemic event under anticoagulation had an
INR less than 3 at the time of recurrence [5]. The bene-
fits of warfarin in the APS are greater than the risks of
bleeding [79].
In SS patients with acute ischemic stroke, thrombolytic
therapy might be safe and effective [81]. Angiotensin con-
verting enzyme inhibitors (ACEI) and prostaglandin E1
(PGE1) have also been used in the treatment of SS [82].
The prevention of smoking and prevention of usage of
estrogen oral contraceptive may prevent or decrease the
severity of neurological symptoms [6]. Moreover, cardiovas-
cular risk factors should also be treated.
Corticosteroids, cyclophosphamide, and azathioprine
have been reported ineffective in treatment of SS [83].
However, one study demonstrated improvements inneurological and cognitive symptoms in a patient after
8 months of monthly intravenous cyclophosphamide
therapy [73]. Future research should focus on identifying
potential subgroups of patients who may be good
responders.
Conclusion
SS is a clinically syndrome that probably stems from a
number of acquired or congenital hemostatic abnormal-
ities which preferentially involves the cerebral and cutane-
ous vascular beds. To a certain extent, the small number
of cases may reflect the unfamiliarity with the syndrome
rather than a true reflection of its incidence. Further
research exploring the pathogenesis of SS is needed to get
more etiological subgroups. Future therapy should identify
different treatment modalities for different etiological
subgroups.
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